You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

228 Results
Guidelines and Advice
Status: Archived
ID: 3-8-2
Version: 2
Sep 2011
Guidelines and Advice
Status: Current
Version: 2
Oct 2018
Guidelines and Advice
Status: Archived
ID: 3-6
Nov 2011
Guidelines and Advice
Status: Archived
ID: 3-8-1
Apr 2013
Guidelines and Advice
Status: Archived
ID: 3-2-1
Oct 2012
Guidelines and Advice
Status: In-Review
ID: GL-3-A-2016-1
Mar 2017
Guidelines and Advice
Status: In-Review
ID: 3-8-4
Version: 2
May 2017
Drug
Other Name(s): Neulasta®, Lapelga®, Fulphila™; Ziextenzo®; Nyvepria™, Niopeg®, Pexegra™
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Drug
Other Name(s): Xgeva®; Wyost™
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2024
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®, Filra™
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - Treatment of metastatic renal cell carcinoma (mRCC) as second or third line therapy in patients
    previously treated for mRCC with a funded tyrosine kinase inhibitor (TKI), with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus
... Show more tags
, Collapse Show fewer tags
Mar 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
durvalumab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025

Pages